Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome

References

• Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113–1121.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59(6):1278–1285.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Pecere S, Lopetuso L, et al. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. Expert Opin Drug Saf. 2016;15(7):983–991.
   PubMed Web of Science ®Google Scholar
• Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012;36(5):437–448.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150(2):358–66.e8.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355(9209):1035–1040.
   PubMed Web of Science ®Google Scholar
• Tong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol. 2013;6(5):344–357.
   PubMed Web of Science ®Google Scholar
• Wade PR, Palmer JM, McKenney S, et al. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/µ opioid receptor antagonist. Br J Pharmacol. 2012;167(5):1111–1125.
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374(3):242–253.
   PubMed Web of Science ®Google Scholar
• Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013;145(2):329–38.e1. Epub 2013/ 04/09.
   PubMed Web of Science ®Google Scholar
• Munjal A, Dedania B, Cash B. Update on pharmacotherapy for irritable bowel syndrome. Curr Gastroenterol Rep. 2019;21(6):25.
   PubMedGoogle Scholar
• Lacy BE. Emerging treatments in neurogastroenterology: eluxadoline – a new therapeutic option for diarrhea-predominant IBS. Neurogastroenterol Motil. 2016;28(1):26–35.
   PubMed Web of Science ®Google Scholar
• Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2017;112(2):365–374.
   PubMed Web of Science ®Google Scholar
• Harinstein L, Wu E, Brinker A. Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder. Aliment Pharmacol Ther. 2018;47(6):809–815.
   PubMed Web of Science ®Google Scholar
• Ida M, Nishida A, Akiho H, et al. Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea. Biopsychosoc Med. 2017;11:8.
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhang Y, Chen F, et al. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018;18(1):5.
   PubMedGoogle Scholar
• Lucak S. Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron. Therap Adv Gastroenterol. 2012;5(4):215–218.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Prestia D, Colicchio S, et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8(3):287–304.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci. 2009;119(6):821–846.
   PubMed Web of Science ®Google Scholar
• Bubenik GA, Brown GM, Grota LJ. Immunohistological localization of melatonin in the rat digestive system. Experientia. 1977;33(5):662–663.
   PubMedGoogle Scholar
• Drago F, Macauda S, Salehi S. Small doses of melatonin increase intestinal motility in rats. Dig Dis Sci. 2002;47(9):1969–1974.
   PubMed Web of Science ®Google Scholar
• Roberts-Thomson IC, Knight RE, Kennaway DJ, et al. Circadian rhythms in patients with abdominal pain syndromes. Aust N Z J Med. 1988;18(4):569–574.
   PubMedGoogle Scholar
• Ray M, Mediratta PK, Mahajan P, et al. Evaluation of the role of melatonin in formalin-induced pain response in mice. Indian J Med Sci. 2004;58(3):122–130.
   PubMedGoogle Scholar
• Shavali S, Ho B, Govitrapong P, et al. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid. Brain Res Bull. 2005;64(6):471–479.
   PubMed Web of Science ®Google Scholar
• Lu WZ, Song GH, Gwee KA, et al. The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig Dis Sci. 2009;54(5):1087–1093.
   PubMed Web of Science ®Google Scholar
• Chojnacki C, Walecka-Kapica E, Lokieć K, et al. Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women. Endokrynol Pol. 2013;64(2):114–120.
   PubMed Web of Science ®Google Scholar
• Kennaway DJ, Wright H. Melatonin and circadian rhythms. Curr Top Med Chem. 2002;2(2):199–209.
   PubMedGoogle Scholar
• Gilbert SS, van Den Heuvel CJ, Dawson D. Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures. J Physiol. 1999;514(Pt 3):905–914.
   PubMed Web of Science ®Google Scholar
• Fass R, Fullerton S, Tung S, et al. Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol. 2000;95(5):1195–2000.
   PubMed Web of Science ®Google Scholar
• Nyhlin H, Ford MJ, Eastwood J, et al. Non-alimentary aspects of the irritable bowel syndrome. J Psychosom Res. 1993;37(2):155–162.
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Palsson OS, Levy RR, et al. Comorbidity in irritable bowel syndrome. Am J Gastroenterol. 2007;102(12):2767–2776.
   PubMed Web of Science ®Google Scholar
• Kopp C, Vogel E, Rettori MC, et al. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav Pharmacol. 1999;10(1):73–83.
   PubMed Web of Science ®Google Scholar
• Saha L, Malhotra S, Rana S, et al. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol. 2007;41(1):29–32.
   PubMed Web of Science ®Google Scholar
• Song GH, Leng PH, Gwee KA, et al. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut. 2005;54(10):1402–1407.
   PubMed Web of Science ®Google Scholar
• Pesce M, D’Alessandro A, Borrelli O, et al. Endocannabinoid-related compounds in gastrointestinal diseases. J Cell Mol Med. 2018;22(2):706–715.
   PubMed Web of Science ®Google Scholar
• Fichna J, Wood JT, Papanastasiou M, et al. Endocannabinoid and cannabinoid-like fatty acid amide levels correlated with pain-related symptoms in patients with IBS-D. and IBS-C: a pilot study. PLoS One. 2013;8(12):e85073. Published online 2013 Dec 27.
   PubMed Web of Science ®Google Scholar
• Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 2008;57(8):1140–1155.
   PubMed Web of Science ®Google Scholar
• Manara L, Croci T, Guagnini F, et al. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig Liver Dis. 2002;34(4):262–269.
   PubMedGoogle Scholar
• Croci T, Manara L, Aureggi G, et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol. 1998;125(7):1393–1395.
   PubMed Web of Science ®Google Scholar
• Aviello G, Romano B, Izzo AA. Cannabinoids and gastrointestinal motility: animal and human studies. Eur Rev Med Pharmacol Sci. 2008;12(Suppl 1):81–93.
   PubMedGoogle Scholar
• Grider JR, Mahavadi S, Li Y, et al. Modulation of motor and sensory pathways of the peristaltic reflex by cannabinoids. Am J Physiol Gastrointest Liver Physiol. 2009;297(3):G539–49.
   PubMed Web of Science ®Google Scholar
• Sibaev A, Yüce B, Kemmer M, et al. Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon. Am J Physiol Gastrointest Liver Physiol. 2009;296(1):G119–28.
   PubMed Web of Science ®Google Scholar
• Yuece B, Sibaev A, Broedl UC, et al. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterol Motil. 2007;19(9):744–753.
   PubMed Web of Science ®Google Scholar
• Fichna J, Sałaga M, Stuart J, et al. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterol Motil. 2014 Apr;26(4):470–481.
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, Busciglio I, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011;141(5):1638–1647.
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, Eckert D, et al. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil. 2012;24(4):358–e169.
   PubMed Web of Science ®Google Scholar
• Barbara G, Cremon C, Bellacosa L, et al. Randomized placebo‐controlled multicenter study on the effect of palmitoyl‐ethanolamide and polydatin on immune activation in patients with irritable bowel syndrome. Gastroenterology. 2014;146:S–124.
   Google Scholar
• Lindstrom BF, Ruckle JL, Turner SA, et al. Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) – preclinical and early clinical development. Inflamm Bowel Dis. 2019;25(Supplement 1):S64.
   Google Scholar
• Yacyshyn B, Ginsberg DC, Gilder K, et al. Su1930 – safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2a study in chronic abdominal pain associated with Crohn’s disease. Gastroenterology. 2019;156(6):S–665.
   Web of Science ®Google Scholar
• Hartmann RM, Fillmann HS, Martins MI, et al. Boswellia serrata has beneficial anti-inflammatory and antioxidant properties in a model of experimental colitis. Phytother Res. 2014;28(9):1392–1398.
   PubMed Web of Science ®Google Scholar
• Madisch A, Miehlke S, Eichele O, et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis. 2007;22(12):1445–1451.
   PubMed Web of Science ®Google Scholar
• Belcaro G, Gizzi G, Pellegrini L, et al. Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome(R)) controls symptoms of mild irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2017;21(9):2249–2254.
   PubMed Web of Science ®Google Scholar
• Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care. 2011;34(Suppl 2):S244–50.
   PubMedGoogle Scholar
• Aziz I, Mumtaz S, Bholah H, et al. High prevalence of idiopathic bile acid diarrhea among patients with diarrhea-predominant irritable bowel syndrome based on Rome III criteria. Clin Gastroenterol Hepatol. 2015;13(9):1650–5.e2.
   PubMed Web of Science ®Google Scholar
• Bajor A, Törnblom H, Rudling M, et al. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut. 2015;64(1):84–92.
   PubMed Web of Science ®Google Scholar
• Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8(2):159–165.
   PubMed Web of Science ®Google Scholar
• Wilson D, Evans M, Weaver E, et al. Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2013;6:49–60.
   PubMedGoogle Scholar
• Didari T, Mozaffari S, Nikfar S, et al. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015;21(10):3072–3084.
   PubMed Web of Science ®Google Scholar
• Lee SH, Cho DY, Han KS, et al. A randomized clinical trial of synbiotics in irritable bowel syndrome: dose-dependent effects on gastrointestinal symptoms and fatigue. Korean J Fam Med. 2019;40(1):2–8.
   PubMed Web of Science ®Google Scholar
• Simren M. Human milk oligosaccharides improve all central symptoms of irritable bowel syndrome: a multi-center, open label trial. Am J Gastroenterol. 2019;114(Suppl 1):S272.
   Google Scholar
• Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol. 1981;3(2):153–156.
   PubMed Web of Science ®Google Scholar
• Boeckxstaens G, Corazziari ES, Mearin F, et al. IBS and the role of otilonium bromide. Int J Colorectal Dis. 2013;28(3):295–304.
   PubMed Web of Science ®Google Scholar
• Boeckxstaens G, Clave P, Corazziari ES, et al. Irritable bowel syndrome: focus on otilonium bromide. Expert Rev Gastroenterol Hepatol. 2014;8(2):131–137.
   PubMed Web of Science ®Google Scholar
• Clavé P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34(4):432–442.
   PubMed Web of Science ®Google Scholar
• Xiao HT, Zhong L, Tsang SW, et al. Traditional Chinese medicine formulas for irritable bowel syndrome: from ancient wisdoms to scientific understandings. Am J Chin Med. 2015;43(1):1–23.
   PubMed Web of Science ®Google Scholar
• Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1350–1365.
   PubMed Web of Science ®Google Scholar